Chemotherapy-induced Thrombocytopenia in Patients With Lymphoma and lung cancer
Conditions
Interventions
rhTPO:Patients will receive 3 periods equally chemotherapy, It is clear to assess the dose and schedule of treatment with rhTPO from Package insert and Expert consensus on diagnosis and treatment of
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Male or female patients at the age of 18 to 75 years old; 2) Histologically or cytologically diagnosed Lymphoma and lung cancer cases; 3) Platele counts is less than or equal to 75*10^9/L during screening chemotherapy cycle, or appears the risk of clinically significant CIT: previous bleeding episodes in last 3 months; baseline platelets less than 75*10^9/L; those patients receiving platinumbased, Cytarabine, anthracycline-based, gemcitabine-based regimen; bone marrow metastases; ECOG PS >=2; received prior radiotherapy (Especially the long bones, flat bones); 4) With understanding ability and voluntarily sign informed consent form; 5) Be able to comply with the study and follow-up process.
Exclusion criteria
Exclusion criteria: 1) Breast-feeding or pregnant women; 2) Platelet count over 400*10^9/L; 3) patients who had severe allergic history on biological preparation; 4) Septicemia, Disseminated intravascular coagulation (DIC), Hypersplenism, ITP, Stem cell transplantation, Leukemia, Bone marrow dysplasia or any other illness sickness that can exacerbate thrombocytopenia appeared in the previous cycles of chemotherapy; 5) The investigator think that the child should not participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood routine examination; | — |
Countries
China
Contacts
Public ContactJifeng Feng
Outcome results
None listed